502486-45-5 Usage
Uses
Used in Pharmaceutical Industry:
1,2,4-Triazolo[4,3-a]pyridine,6-nitro-(9CI) is used as a key intermediate in the synthesis of novel drugs and pharmaceutical formulations. Its unique structure and properties make it a promising candidate for the development of new therapeutic agents.
Used in Research Applications:
In the research field, 1,2,4-Triazolo[4,3-a]pyridine,6-nitro-(9CI) serves as a valuable compound for studying the properties and behavior of heterocyclic compounds. It aids in understanding the structure-activity relationships and the potential applications of similar compounds in various fields.
Used in Organic Synthesis:
1,2,4-Triazolo[4,3-a]pyridine,6-nitro-(9CI) is used as a versatile building block in organic synthesis. Its nitro group allows for the synthesis of various derivatives with potentially useful properties, contributing to the development of new chemical entities and materials.
Used in Material Science:
1,2,4-Triazolo[4,3-a]pyridine,6-nitro-(9CI) may also have potential applications in the field of material science, where its unique structure and properties can be utilized to develop new materials with specific characteristics, such as improved stability, reactivity, or selectivity.
Check Digit Verification of cas no
The CAS Registry Mumber 502486-45-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,0,2,4,8 and 6 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 502486-45:
(8*5)+(7*0)+(6*2)+(5*4)+(4*8)+(3*6)+(2*4)+(1*5)=135
135 % 10 = 5
So 502486-45-5 is a valid CAS Registry Number.
502486-45-5Relevant academic research and scientific papers
SUBSTITUTED OXOPYRIDINE DERIVATIVES
-
Paragraph 0539; 0540, (2016/10/11)
The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.
